Clinical data
| Patient/ sample* . | Sex . | Age (y) . | Current infectious manifestations† . | Treatment‡ (starting) . | CD4 (cells/μL) . | CD8 (cells/μL) . | HIV RNA (copies/mL) . |
|---|---|---|---|---|---|---|---|
| T8/M0 | M | 38 | d4T/ddI | 65 | 1 230 | 29 260 | |
| T8/M1 | Ind/d4T/ddI | 82 | 1 059 | 7 989 | |||
| T8/M4 | Ind/d4T/ddI | 131 | 1 369 | 1 064 | |||
| T8/M19 | B3 | Ind/d4T/3TC | 318 | n.d. | < 200 | ||
| T8/M30 | Ind/d4T/3TC | 485 | n.d. | < 200 | |||
| T11/M0 | M | 38 | AZT/3TC | 27 | 499 | 322 000 | |
| T11/M1 | Ind/AZT/3TC | 100 | 1 028 | 12 000 | |||
| T11/M6 | Ind/AZT/3TC | 122 | 1 466 | 331 | |||
| T11/M17 | Ind/AZT/3TC | 207 | 1 817 | < 200 | |||
| T11/M31 | Ind/AZT/3TC | 261 | 1 573 | 175 | |||
| T13/M0 | M | 61 | Ind/AZT/3TC | 30 | 378 | 420 000 | |
| T13/M1 | C9 | Ind/AZT/3TC | 18 | 598 | 11 506 | ||
| T13/M6 | Ind/d4T/3TC | 15 | 480 | 9 620 | |||
| T13/M10 | Ind/d4T/3TC | 7 | 544 | 18 200 | |||
| T16/M0 | M | 41 | Ind/AZT/ddC | 40 | 520 | 515 000 | |
| T16/M1 | Ind/AZT/ddC | 169 | 1 410 | 93 900 | |||
| T16/M6 | Ind/AZT/ddC | 152 | 660 | 400 | |||
| T16/M14 | B3 | Ind/AZT/3TC | 163 | 788 | 104 600 | ||
| T16/M26 | Ind/NVP/d4T/ddI | 144 | 886 | 345 200 | |||
| T16/M30 | Ind/NVP/d4T/ddI | 150 | 663 | 22 300 | |||
| 1-153T17/M0 | M | 40 | Ind/AZT/ddI | 36 | 560 | 1 500 000 | |
| T17/M1 | Ind/AZT/ddI | 93 | 599 | 5 363 | |||
| T17/M6 | Ind/AZT/ddI | 197 | 1 000 | 323 | |||
| T17/M9 | Ind/AZT/ddI | 155 | 566 | < 200 | |||
| T17/M12 | Ind/AZT/ddI | 230 | 693 | < 200 | |||
| 1-153T18/M0 | M | 39 | Ind/AZT/3TC | 136 | 1 091 | 99 365 | |
| T18/M1 | Ind/AZT/3TC | 181 | 1 156 | 1 124 | |||
| T18/M6 | Ind/AZT/3TC | 195 | 1 335 | < 200 | |||
| T18/M9 | Ind/AZT/3TC | 280 | 841 | < 200 | |||
| T18/M12 | Ind/AZT/3TC | 225 | 788 | < 200 | |||
| T18/M28 | Ind/AZT/3TC | 162 | 858 | 2 674 | |||
| 1-153T19/M0 | M | 31 | Rit/d4T/ddI | 299 | 479 | 129 800 | |
| T19/M1 | Rit/d4T/ddI | 465 | 579 | 4 400 | |||
| T19/M3 | Rit/d4T/ddI | 579 | 540 | 680 | |||
| T19/M6 | Rit/d4T/ddI | 565 | 474 | < 200 | |||
| T19/M12 | 3TC/d4T | 679 | 503 | 1 000 | |||
| T19/M20 | 3TC/d4T | 977 | 734 | 700 | |||
| 1-153T20/M0 | M | 36 | Ind/AZT/ddC | 92 | 1 635 | 101 393 | |
| T20/M1 | Ind/AZT/ddC | 186 | 953 | 1 213 | |||
| T20/M3 | Ind/AZT/ddC | 217 | 1 346 | < 200 | |||
| T20/M6 | Ind/AZT/ddC | 276 | 1 017 | < 200 | |||
| T20/M12 | Ind/AZT/ddC | 203 | 888 | < 200 |
| Patient/ sample* . | Sex . | Age (y) . | Current infectious manifestations† . | Treatment‡ (starting) . | CD4 (cells/μL) . | CD8 (cells/μL) . | HIV RNA (copies/mL) . |
|---|---|---|---|---|---|---|---|
| T8/M0 | M | 38 | d4T/ddI | 65 | 1 230 | 29 260 | |
| T8/M1 | Ind/d4T/ddI | 82 | 1 059 | 7 989 | |||
| T8/M4 | Ind/d4T/ddI | 131 | 1 369 | 1 064 | |||
| T8/M19 | B3 | Ind/d4T/3TC | 318 | n.d. | < 200 | ||
| T8/M30 | Ind/d4T/3TC | 485 | n.d. | < 200 | |||
| T11/M0 | M | 38 | AZT/3TC | 27 | 499 | 322 000 | |
| T11/M1 | Ind/AZT/3TC | 100 | 1 028 | 12 000 | |||
| T11/M6 | Ind/AZT/3TC | 122 | 1 466 | 331 | |||
| T11/M17 | Ind/AZT/3TC | 207 | 1 817 | < 200 | |||
| T11/M31 | Ind/AZT/3TC | 261 | 1 573 | 175 | |||
| T13/M0 | M | 61 | Ind/AZT/3TC | 30 | 378 | 420 000 | |
| T13/M1 | C9 | Ind/AZT/3TC | 18 | 598 | 11 506 | ||
| T13/M6 | Ind/d4T/3TC | 15 | 480 | 9 620 | |||
| T13/M10 | Ind/d4T/3TC | 7 | 544 | 18 200 | |||
| T16/M0 | M | 41 | Ind/AZT/ddC | 40 | 520 | 515 000 | |
| T16/M1 | Ind/AZT/ddC | 169 | 1 410 | 93 900 | |||
| T16/M6 | Ind/AZT/ddC | 152 | 660 | 400 | |||
| T16/M14 | B3 | Ind/AZT/3TC | 163 | 788 | 104 600 | ||
| T16/M26 | Ind/NVP/d4T/ddI | 144 | 886 | 345 200 | |||
| T16/M30 | Ind/NVP/d4T/ddI | 150 | 663 | 22 300 | |||
| 1-153T17/M0 | M | 40 | Ind/AZT/ddI | 36 | 560 | 1 500 000 | |
| T17/M1 | Ind/AZT/ddI | 93 | 599 | 5 363 | |||
| T17/M6 | Ind/AZT/ddI | 197 | 1 000 | 323 | |||
| T17/M9 | Ind/AZT/ddI | 155 | 566 | < 200 | |||
| T17/M12 | Ind/AZT/ddI | 230 | 693 | < 200 | |||
| 1-153T18/M0 | M | 39 | Ind/AZT/3TC | 136 | 1 091 | 99 365 | |
| T18/M1 | Ind/AZT/3TC | 181 | 1 156 | 1 124 | |||
| T18/M6 | Ind/AZT/3TC | 195 | 1 335 | < 200 | |||
| T18/M9 | Ind/AZT/3TC | 280 | 841 | < 200 | |||
| T18/M12 | Ind/AZT/3TC | 225 | 788 | < 200 | |||
| T18/M28 | Ind/AZT/3TC | 162 | 858 | 2 674 | |||
| 1-153T19/M0 | M | 31 | Rit/d4T/ddI | 299 | 479 | 129 800 | |
| T19/M1 | Rit/d4T/ddI | 465 | 579 | 4 400 | |||
| T19/M3 | Rit/d4T/ddI | 579 | 540 | 680 | |||
| T19/M6 | Rit/d4T/ddI | 565 | 474 | < 200 | |||
| T19/M12 | 3TC/d4T | 679 | 503 | 1 000 | |||
| T19/M20 | 3TC/d4T | 977 | 734 | 700 | |||
| 1-153T20/M0 | M | 36 | Ind/AZT/ddC | 92 | 1 635 | 101 393 | |
| T20/M1 | Ind/AZT/ddC | 186 | 953 | 1 213 | |||
| T20/M3 | Ind/AZT/ddC | 217 | 1 346 | < 200 | |||
| T20/M6 | Ind/AZT/ddC | 276 | 1 017 | < 200 | |||
| T20/M12 | Ind/AZT/ddC | 203 | 888 | < 200 |
Blood was sampled just before treatment (M0) and at 1 to 32 months (M1 to M32) after the onset of treatment.
CDC 1993 definition of AIDS stage and AIDS-related infections (B3, herpes zoster; C9, esophageal candidiasis).
d4T, stavudine; ddI, didanosine; Ind, indinavir; AZT, zidovudine; 3TC, lamivudine; NVP, nevirapine; Rit, ritonavir.
Naive patients. All other patients receiving triple therapy were pretreated.